# Pizarra — PT-pseudo_c13fda040310 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c13fda040310
Task: 1

Encounter: Urology - outpatient on 19 Feb 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 6.1 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.08 ng/mL²
  - PSA velocity: 1.35 ng/mL/yr
  - Prior PSA: 4.9 ng/mL
  - Prostate volume: 73.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.81674135 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes, Hypercholesterolaemia, Osteoarthritis, Benign prostatic hyperplasia
  - Problem list / PMHx: Type 2 diabetes, Hypercholesterolaemia, Osteoarthritis, Benign prostatic hyperplasia
  - Current medication: metformin, empagliflozin, atorvastatin, simvastatin, rosuvastatin, paracetamol PRN, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 6.1 ng/mL. PI-RADS 4. PSAD 0.08. Prostate volume 73 mL. csPCa 0.82.

Vitals: weight 81 kg, height 180 cm, BMI 25.0, BP 125/95 mmHg, HR 72 bpm. Smoking: Current smoker (23 pack-yr).

Chief complaint: An escalating PSA trajectory reaching 6.1 ng/mL after a previously negative systematic biopsy necessitates specialist re-evaluation.

History: Divorced and currently residing with a partner, the 63-year-old freelance translator entered initial prostate cancer risk assessment in mid-2023 following a PSA reading of 3.5 ng/mL. Over the subsequent two years, he has experienced a steady, asymptomatic PSA increase now reaching 6.1 ng/mL. Despite the earlier negative biopsy, he expresses considerable apprehension regarding another invasive procedure. Lower urinary tract symptoms remain minimal (IPSS 5), adequately controlled with tamsulosin and a routine of commuter cycling five times each week. His clinical background includes benign prostatic hyperplasia, well-managed type 2 diabetes treated with metformin and empagliflozin, as well as hypercholesterolaemia addressed through atorvastatin, simvastatin, and rosuvastatin. He maintains an active lifestyle despite being a current smoker with a 23 pack-year history. He explicitly denies haematuria, pelvic pain, or unexplained weight loss. A stable, decades-long right knee osteoarthritis restricts his marathon goals and occasionally requires paracetamol PRN. Weekly alcohol intake averages one unit, and he notes that extended hours spent translating technical documents frequently contribute to his general fatigue.

Physical examination: DRE — texture: smooth and firm; mobility: unrestricted; asymmetry: none. The prostate is symmetrically enlarged but otherwise unremarkable, confirming a normal digital rectal examination. General physical assessment shows no abnormalities, with clear cardiovascular and respiratory auscultation, absent peripheral lymphadenopathy, and no palpable abdominal masses.

Patient info: freelance translator; Divorced; Lives with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 1 units / week; exercise Cycling 5x/week (commuter); IPSS score: 5/35 (mild LUTS).


Admin: Patient anxious about procedures — allocate extra consult time.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.53 +/- 0.20   (95% CI 0.14-0.90)

Where the uncertainty comes from:
  - aleatoric  dA = 0.17  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 5.4 effective neighbours out of 10; 2 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=1.0, psa=6.1, age=63.0, psad=0.08, dre_ord=0.0, vol=73.0, n_pmhx=4.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior negative biopsy.

CRITERION VERDICT: BIOPSY.

The criterion: Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

In the labelled cohort this criterion matched the reading urologist in 16 of the 18 cases with a prior negative biopsy.

Track record of this criterion on the labelled cohort: 16 of 18 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only used the visible panel data (PI-RADS 4, PSA 6.1, prior negative biopsy, etc.). It could not account for the patient's rising PSA velocity (1.35 ng/mL/yr) or the specific PSA trajectory (from 3.5 ng/mL to 6.1 ng/mL over two years). It also ignored the clinical context that the patient is anxious about procedures and has minimal LUTS (IPSS 5), which might influence the decision beyond the raw scores.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested BIOPSY with a wide uncertainty interval (0.53 +/- 0.20). The wide aleatoric error (dA = 0.17) indicates the nearest labelled cases disagree significantly, meaning the classifier cannot reliably distinguish between biopsy and no biopsy for this profile. Furthermore, the protocol expert's criterion suggests that a PI-RADS 4 lesion warrants biopsy, but the prior failed to weigh the clinical context that a prior negative biopsy should temper this decision.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI? - if it is unchanged the case for sampling weakens; if new or larger it strengthens
PSA history - to confirm the rate of PSA increase and trajectory
previous GP / urology notes - to assess the clinical context regarding patient anxiety and LUTS
laboratory panel - to check for any relevant laboratory markers that might modify the risk assessment
family-history anamnesis - to assess genetic risk factors

GUIDELINE ANCHOR
The guideline suggests that a PI-RADS $\ge 3$ threshold is used to trigger biopsy, and repeat biopsy after a negative biopsy depends on risk factors like PSA density.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_c13fda040310", "radiology_report": "Radiology Division | Catharina Ziekenhuis, Eindhoven | 15 Feb 2025 | Multiparametric MRI Prostate\n\nClinical context: 63-year-old male with escalating PSA trajectory (latest 6.1 ng/mL) and prior negative systematic biopsy. Re-evaluation for targeted sampling.\n\nFINDINGS:\nThe gland measures 73.0 mL in total volume. Within the left mid-gland posterior peripheral zone, a focal lesion (approximately 12 x 9 x 11 mm) demonstrates restricted diffusion alongside early contrast enhancement. T2-weighted sequences show low signal intensity, while high b-value DWI (b=1400) reveals marked hypointensity. Dynamic contrast imaging confirms a focal early enhancement pattern. The transition zone exhibits moderate benign prostatic hyperplasia with cystic degeneration, aligning with the patient\u2019s age and lower urinary tract symptom profile. There is no evidence of extracapsular extension or seminal vesicle invasion.\n\nIMPRESSION:\nPI-RADS: 4\nprostate volume: 73.0\nPSA density: 0.08\ncsPCa probability: 0.81674135"}
get_psa_trend
{"case_id": "PT-pseudo_c13fda040310", "psa_trend": [{"date": "Jun 2023", "val": 1.4}, {"date": "Jan 2024", "val": 2.3}, {"date": "Aug 2024", "val": 3.7}, {"date": "Feb 2025", "val": 6.1}]}
get_previous_notes
{"case_id": "PT-pseudo_c13fda040310", "previous_notes": [{"date": "24 Jun 2024", "author": "Dr. E. Mulder (GP)", "text": "A January 2024 assay recorded a PSA of 4.6 ng/mL, marking a continued ascent from the 3.5 ng/mL value noted the previous June. Due to this persistent elevation coupled with mild lower urinary tract symptoms, a systematic transrectal ultrasound-guided biopsy was carried out in June 2024. Histological analysis returned entirely benign, with no signs of malignancy."}, {"date": "29 Aug 2023", "author": "Dr. E. Mulder (GP)", "text": "An initial screening measurement in June 2023 yielded 3.5 ng/mL. The individual experiences occasional nocturia and a diminished urinary stream, which have been addressed through conservative measures. Given his age alongside this borderline elevation, an assessment was initiated at the urology outpatient clinic to facilitate comprehensive risk stratification and further investigation."}]}
get_lab_results
{"case_id": "PT-pseudo_c13fda040310", "laboratory_results": [{"name": "PSA", "val": "6.1 ng/mL", "date": "04 Feb 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.30 ng/mL", "date": "04 Feb 2025", "flag": ""}, {"name": "%Free PSA", "val": "21%", "date": "04 Feb 2025", "flag": ""}, {"name": "Haemoglobin", "val": "15.1 g/dL", "date": "04 Feb 2025", "flag": ""}, {"name": "WBC", "val": "5.5 x10^9/L", "date": "04 Feb 2025", "flag": ""}, {"name": "Platelets", "val": "201 x10^9/L", "date": "04 Feb 2025", "flag": ""}, {"name": "Creatinine", "val": "98 umol/L", "date": "04 Feb 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "04 Feb 2025", "flag": ""}, {"name": "Testosterone", "val": "11.3 nmol/L", "date": "04 Feb 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "74 U/L", "date": "04 Feb 2025", "flag": ""}, {"name": "LDH", "val": "226 U/L", "date": "04 Feb 2025", "flag": ""}]}

NOT RETRIEVED
The pathology report was not retrieved because the prompt stated it was not on file for this task.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling:
- mpMRI report: PI-RADS score of 4 with a focal lesion (12 x 9 x 11 mm) showing restricted diffusion and early enhancement.
- PSA trend: Rising trajectory from 3.5 ng/mL (Jun 2023) to 6.1 ng/mL (Feb 2025), indicating an escalating PSA velocity.
- Previous notes: Prior systematic biopsy was negative, and the patient is re-evaluating due to escalating PSA.

AGAINST Sampling:
- Previous notes: Prior biopsy was negative.
- DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).

WHERE THIS LEANS
The evidence strongly supports proceeding with a targeted biopsy due to the PI-RADS 4 finding on the MRI and the concerning rising PSA trajectory, despite the prior negative result.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to proceed with a targeted biopsy is driven by the PI-RADS 4 score on the mpMRI, which is decisive in this context. This finding is supported by the retrieved radiology report showing a focal lesion with restricted diffusion. Furthermore, the rising PSA trajectory, from 3.5 ng/mL to 6.1 ng/mL, adds clinical urgency. The prior negative biopsy is outweighed by the new, high-risk imaging finding, leading to a clear recommendation for further sampling.

Variables that carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
